Key result
Heart failure medical therapy optimization across left ventricular ejection fraction strata is crucial for improving morbidity and mortality, particularly prior to device-based therapies.
Why the study?
Heart failure medical therapy has expanded rapidly, and its optimization is crucial for interventional and structural cardiologists prior to device-based therapies or clinical trial enrollment.
Optimization of heart failure medical therapy is crucial for patients undergoing structural or interventional cardiology procedures to reduce periprocedural morbidity and mortality.
Prioritizes GDMT optimization before structural interventions; leaves open need for prospective trials across LVEF strata.
Medical therapy for heart failure (HF) has expanded rapidly in the last decade contributing to improved morbidity and mortality for patients living with HF. The indicated treatments have been traditionally stratified based on left ventricular ejection fraction. The optimization of HF medical therapy is important for interventional and structural cardiologists as HF remains among the most common causes of periprocedural hospitalization and death. Additionally, optimization of medical therapy for HF prior to the utilization of device-based therapies as well as enrollment in clinical trials is crucial. This review will serve to highlight medical therapy indicated across the left ventricular ejection fraction strata.
No takes yet. Share an insight, caveat, or question.
Pipilas et al. (2022) conducted a review in Heart failure. Heart failure medical therapy was evaluated. Heart failure medical therapy optimization across left ventricular ejection fraction strata is crucial for improving morbidity and mortality, particularly prior to device-based therapies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: